Update on International Generic Drug Regulators Pilot

19 August 2015

The International Generic Drug Regulators Pilot (IGDRP) was launched in April 2012 in the face of mounting pressures that confront generic drug review programs worldwide and a willingness on the part of regulatory agencies to pursue collaboration and convergence to help mitigate these pressures.

The IGDRP operated for a three-year period on interim operating procedures for the Pilot. The seventh and final meeting of the International Generic Drug Regulators Pilot took place in Singapore, November 2 to 5, 2014.

The IGDRP Steering Committee recognized the considerable progress made by the Pilot and recommended extending the initiative for a further two years, from January 2015 to December 2016 and to change the initiative's name to 'International Generic Drug Regulators Program'.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics